Aprea Therapeutics Inc.
APRE | NASDAQ
$0.74
-$0.02 (-2.62%)
At close: Sep 21, 2026, 4:00 PM ET
$0.80
+$0.06 (+8.11%)
After-hours:
Sep 21, 2026, 7:50 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | 1.5M | 583.23K | n/a | n/a | n/a |
Cost of Revenue | n/a | 9.36M | 7.05K | 16.4M | 271.68K | 229.61K |
Gross Profit | n/a | -7.86M | 576.18K | -16.4M | -271.68K | -229.61K |
Operating Income | -13.23M | -14.32M | -15.47M | -113.39M | -37.45M | -52.81M |
Interest Income | 652.09K | 1.29M | 1.22M | 448.67K | 1.65K | 222.65K |
Pretax Income | -12.6M | -12.96M | -14.29M | -112.66M | -37.13M | -53.48M |
Net Income | -12.6M | -12.96M | -14.29M | -112.66M | -36.54M | -53.92M |
Selling & General & Admin | 6.48M | 6.46M | 8.42M | 20.97M | 13.55M | 14.93M |
Research & Development | 7.04M | 9.36M | 7.63M | 92.42M | 23.9M | 37.88M |
Other Expenses | -285.76K | -9.36M | n/a | -16.4M | -271.68K | n/a |
Operating Expenses | 13.23M | 6.46M | 16.05M | 96.99M | 37.17M | 52.81M |
Interest Expense | n/a | n/a | n/a | 448.67K | n/a | 222.65K |
Selling & Marketing Expenses | n/a | n/a | -7.05K | n/a | n/a | n/a |
Cost & Expenses | 13.23M | 15.82M | 16.06M | 113.39M | 37.45M | 52.81M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 6.54M | 5.51M | 3.62M | 82.85K | 1.06M | 1.06M |
Shares Outstanding (Diluted) | 6.54M | 5.51M | 3.62M | 82.85K | 1.06M | 1.06M |
EPS (Basic) | -1.93 | -2.35 | -3.95 | -1.36K | -34.88 | -50.61 |
EPS (Diluted) | -1.93 | -2.35 | -3.95 | -1.36K | -34.88 | -50.61 |
EBITDA | -12.58M | -12.94M | -14.28M | -37.37M | -36.86M | -53.25M |
EBIT | -12.6M | -12.96M | -14.29M | -37.37M | -37.13M | -53.48M |
Depreciation & Amortization | 21.72K | 22.32K | 7.05K | 4.4K | 271.68K | 229.61K |
Add to Watchlist
Select watchlists to add or remove APRE